Abemaciclib as adjuvant treatment for high-risk early breast cancer

CONCLUSIONS: The results of the pivotal trial are sufficient to consider abemaciclib as adjuvant treatment for high-risk early breast cancer in highly selected patients. However, in order to the efficacy results present less uncertainty, we must wait for a evaluation later, in which we can have a mature determination at 3 years (with more patients at risk).PMID:38114413 | DOI:10.1016/j.farma.2023.10.010

Source: Farmacia Hospitalaria - December 19, 2023 Category: Drugs & Pharmacology Authors: Ana Ganfornina Andrades Silvia F énix Caballero Alba Salguero Olid Emilio Jes ús Alegre Del-Rey Source Type: research